Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

ofloxacin (Rx)Brand and Other Names:Floxin

 
 
 

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

tablet

  • 200mg
  • 300mg
  • 400mg
more...

Bronchitis Exacerbation, Community Acquired Pneumonia, Skin Infection

400 mg PO q12hr for 10 days

Acute, Uncomplicated Urethral and Cervical Gonorrhea

No longer recommended for gonorrhea due to widespread resistance in the US

400 mg PO single dose

Nongonococcal Cervicitis/Urethritis or Mixed Infection of Cervix/Urethra

300 mg PO q12hr for 7 days

Acute Pelvic Inflammatory Disease

400 mg PO q12hr for 10-14 days

Uncomplicated Cystitis

Due to E. coli or K. pneumoniae: 200 mg PO q12hr for 3 days

Due to other approved pathogens: 200 mg PO q12hr for 7 days

Complicated UTIs

200 mg PO q12hr for 10 days

Prostatitis Due to E. Coli

300 mg PO q12hr for 6 weeks

Traveler's Diarrhea (Off-label)

300 mg PO q12hr for 1-3 days

Renal Impairment

20-50 mL/min: Give q24hr

<20 ml/min: Give one-half usual dose q24hr

Other Information

Do not take with antacids or dairy products

All parenteral forms discontinued in the U.S.

Other Indications and Uses

Mild to moderate infection due to susceptible strains of designated microorganisms

Chlamydia trachomatis, Citrobacter spp, Enterobacter spp, E. coli, Klebsiella pneumoniae, N. gonorrhoeae, Proteus mirabilis, Pseudomonas aeruginosa, S. aureus, S. pneumoniae

Culture and susceptibility tests needed to isolate and identify organisms

Not indicated

Next

Interactions

Interaction Checker

ofloxacin and

No Results

     
     activity indicator 
    No Interactions Found
    Interactions Found

    Contraindicated

      Serious - Use Alternative

        Significant - Monitor Closely

          Minor

            Sort by :  
             activity indicator 
            Previous
            Next

            Adverse Effects

            1-10%

            Nausea (3-10%)

            Headache (1-9%)

            Insomnia (3-7%)

            Dizziness (1-5%)

            Vaginitis (1-5%)

            Diarrhea (1-4%)

            Vomiting (1-4%)

            Appetite decreased (1-3%)

            Abdominal cramps (1-3%)

            Abnormal taste (1-3%)

            Chest pain (1-3%)

            External genital pruritis in women (1-3%)

            Fatigue (1-3%)

            Flatulence (1-3%)

            GI distress (1-3%)

            Nervousness (1-3%)

            Pharyngitis (1-3%)

            Pyrexia (1-3%)

            Rash/pruritis (1-3%)

            Sleep disorders (1-3%)

            Visual disturbances (1-3%)

            Xerostomia (1-3%)

            <1%

            Prolonged QT interval

            Torsades de pointes

            Syncope

            Vasculitis

            Edema

            HTN

            Palpitations

            Vasodilation

            Stevens-Johnson syndrome

            Toxic epidermal necrolysis

            Agranulocytosis

            Aplastic anemia

            Pancytopenia

            Thrombocytopenia

            Thrombocytopenic purpura

            Acute hepatitis

            Hepatic failure

            Hepatic necrosis

            Immune hypersensitivity reaction

            Rupture of tendon, Tendinitis

            Peripheral neuropathy

            Seizure

            Acute renal failure

            Interstitial nephritis

            Renal impairment

            Tourette's syndrome

            Decr hearing acuity

            Tinnitus

            Previous
            Next

            Warnings

            Black Box Warnings

            Fluoroquinolones are associated with an increased risk of tendinitis and tendon rupture; this risk is further increased in older patients, usually those older than 60 years; in kidney, heart, and lung transplant recipients; and with use of concomitant steroid therapy

            May exacerbate muscle weakness in patients with myasthenia gravis; avoid fluoroquinolones with known history of myasthenia gravis

            Contraindications

            Documented hypersensitivity

            Cautions

            May produce false-positive urine opiate screening

            No longer recommended for gonorrhea due to widespread resistance in the US

            In prolonged therapy, perform periodic evaluations of organ system functions (eg, renal, hepatic, hematopoietic); adjust dose in renal function impairment; superinfections may occur with prolonged or repeated antibiotic therapy

            Not drug of first choice in pediatrics due to increased incidence of adverse events compared to controls, including arthropathy; no data exist for dose for pediatric patients with renal impairment (ie, CrCl <50 mL/min)

            Convulsions, increased intracranial pressure (including pseudotumor cerebri), and toxic psychosis reported with fluoroquinolones

            Acute onset of retinal detachment increased 4.5-fold with oral fluoroquinolones in a single case-controlled study - JAMA 2012;307(13):1414-1419; another study disputes these findings (relative risk, 1.29) - JAMA 2013;310(20):2184-2190

            Peripheral neuropathy

            • Peripheral neuropathy may occur rapidly after initiating therapy and may potentially become permanent
            • Development of peripheral neuropathy appears to be unrelated to the duration of therapy or the age of the patient
            • If peripheral neuropathy develops, discontinue the fluoroquinolone and treat with an alternative non-fluoroquinolone antibacterial drug, unless the benefit of continued treatment with a fluoroquinolone outweighs the risk
            Previous
            Next

            Pregnancy & Lactation

            Pregnancy Category: C

            Lactation: excreted in breast milk, discontinue drug or do not nurse

            Pregnancy Categories

            A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

            B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

            C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

            D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

            X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

            NA:Information not available.

            more...
            Previous
            Next

            Pharmacology

            Mechanism of Action

            Inhibits bacterial DNA gyrase, which in turn inhibits DNA replication and transcription, DNA repair, recombination and transposicion, causing bacterial cell death.

            Absorption

            Well absorbed; food causes only minor alterations

            Bioavailability: 98%

            Distribution

            Protein Bound: 32%

            Vd: 2.4-3.5 L/kg

            Elimination

            Half-Life: 4-5 hr

            Excretion: Urine (up to 80% unchanged; <5% metabolites); feces 4-8%

            Previous
            Next

            Administration

            IV Incompatibilities

            Y-site: amphotericin B cholesteryl sulfate, cefepime, doxorubicin liposomal

            IV Preparation

            Solution: dilute single dose vial to 4 mg/mL w/ NS

            Previous
            Next

            Images

            Previous
            Next

            Formulary

            FormularyPatient Discounts

            To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

            Adding plans allows you to:

            • View the formulary and any restrictions for each plan.
            • Manage and view all your plans together – even plans in different states.
            • Compare formulary status to other drugs in the same class.
            • Access your plan list on any device – mobile or desktop.

            The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

            Tier Description
            1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
            2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
            3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
            4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            NC NOT COVERED – Drugs that are not covered by the plan.
            Code Definition
            PA Prior Authorization
            Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
            QL Quantity Limits
            Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
            ST Step Therapy
            Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
            OR Other Restrictions
            Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
            Add or Remove Plans
            Plans for
            Select State:
            Non-Medicare PlansMedicare Plans

            Select a box to add or remove a plan.

            Select a class to view formulary status for similar drugs

            Additional Offers
            Email to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Email Forms to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Previous
             
             
             
            All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.